Evercore ISI removes IBM stock from tactical list after earnings

IBM reported Q1 revenue of $15.9 billion, ahead of the $15.6 billion consensus, while non-GAAP EPS of $1.91 beat estimates by $0.10. Revenue rose 9.5% year over year on a reported basis, with software up 11.3%, infrastructure up 15.2%, and free cash flow of $2.2 billion; the company also maintained guidance. Evercore ISI reiterated an Outperform rating and $310 price target but removed IBM from its Tactical Outperform list, highlighting a mixed but constructive setup.

Analysis

The main takeaway is not that IBM had a good quarter; it is that the market is still pricing it like a low-growth legacy software vendor while the business is increasingly behaving like a cash-generative AI/infrastructure compounder. The second-order effect is on factor rotation: if rates stay sticky and software multiples remain compressed, IBM’s mix of recurring software, durable services, and capital returns becomes relatively more attractive than higher-duration peers whose valuations depend on future AI monetization. That makes the stock more sensitive to incremental evidence of sustained free cash flow and less sensitive to near-term earnings beats.

The real risk is that AI positioning becomes narrative inflation without a commensurate reacceleration in the core consulting business. If consulting remains soft for another 1-2 quarters, investors may conclude that AI is cannibalizing rather than expanding demand, which would cap multiple expansion despite solid margins. In that scenario, the stock can underperform even with stable fundamentals because the market will discount the durability of the software-led mix shift.

A more contrarian read is that the market may be underestimating the optionality embedded in IBM’s capital allocation and adjacent bets. With a large cash flow base and a long dividend record, even modest multiple expansion can create meaningful upside if management continues to defend margins and keep buybacks active. The asymmetric setup is not a hypergrowth rerate; it is a de-rating reversal if IBM proves it can grow mid-single digits while maintaining high-50s gross margins and low-teens pre-tax margins over several quarters.

The competitive implication is that IBM is less threatened by pure software names than by IT services and infrastructure vendors that lack a similar cash-return profile. If enterprise buyers favor trusted, governed AI tools over open-ended copilots, IBM can win share in regulated workflows where security and auditability matter more than model novelty. That creates a slower-burn but durable advantage that should show up first in bookings quality and then in margin resilience, not in headline revenue acceleration.

Key Decisions for Investors

• Go long IBM on 3-6 month horizon; favor entry on weakness near technical support, with a target of mid-240s to low-260s if the market starts paying for cash flow durability rather than headline growth.
• Pair trade: long IBM / short a basket of high-multiple enterprise software names over 1-3 months. The thesis is multiple compression persists for duration-sensitive software while IBM’s cash generation and dividend support create downside protection.
• Buy IBM call spreads 3-6 months out to express rerating upside with defined risk. Structure for a modest move higher rather than a breakout story; best if you want convexity on continued margin resilience.
• If holding IBM, use any rally driven by AI headlines to trim 20-30% and re-add only after the next earnings confirmation. The risk/reward improves materially if the market becomes skeptical again and the stock trades on cash flow, not story.
• Avoid chasing HSBC on the valuation-of-quantum angle; treat that as long-dated optionality only. The near-term trade is still IBM core business execution, not quantum monetization.